High-dose 5-fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-fluorouracil incorporation into RNA in murine tumors

Oncology

Volumn 62, Issue 4, 2002, Pages 363-370

  Codacci Pisanelli, Giovanni ^a   Van Der Wilt, Clasina L ^b   Smid, Kees ^b   Noordhuis, Paul ^b   Voorn, Daphne ^b   Pinedo, Herbert M ^b   Peters, Godefridus J ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 Fluorouracil; Leucovorin; Thymidylate synthase; Uridine diphosphoglucose

Indexed keywords

FLUOROURACIL; RNA; THYMIDYLATE SYNTHASE; URIDINE DIPHOSPHATE GLUCOSE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; MICE; MICE, INBRED BALB C; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; THYMIDYLATE SYNTHASE; URIDINE DIPHOSPHATE GLUCOSE;

EID: 0036060421     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065069     Document Type: Article

References (39)

1. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer
2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
3. Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma
4. High-dose 5-fluorouracil with delayed uridine 'rescue' in mice
5. Biochemical modulation: Perspectives and objectives
6. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil
7. Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil
8. Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats: Effect of high-dose uridine
9. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine
10. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-l-aspartate, methotrexate and leucovorin
11. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer
12. Clinical and pharmacokinetic study of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity
13. Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue
14. Uridine rescue of the FUra toxicity. The possible role of uridine diphosphoglucose (UDPG)
15. Modulation of 5-fluorouracil in mice using uridine diphosphoglucose
16. 5-Fluorouracil: Biochemistry and pharmacology
17. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells
18. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
19. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine Colon 26-b carcinoma tumor model
20. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue - Correlation of anti-tumor activity with dosage and FUra incorporation into RNA
21. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors
22. Antitumor activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice
23. 18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: A study for a correlation with oncological results
24. Sensitivity of human, murine and rat cells to 5-fluorouracil and 5)-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes
25. Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil
26. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma
27. Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas-chromatography-mass spectrometry assay
28. In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas
29. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro
30. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions
31. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma
32. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation
33. Clinical relevance of biochemical modulation of 5-fluorouracil
34. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
35. Effective biomodulation by leucovorin of high dose infusional fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
36. Mechanism of induction of the gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′)-deoxyuridine
37. Inhibition of uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence of the involvement of RNA perturbation
38. Potential role of 5-fluorouracil incorporation into RNA and DNA of murine and human colon tumors
39. Triacetyluridine (TAU) as rescue from 5-fluorouracil (FU) toxicity allows increased FU dose intensity when given with N-phosphonacetyl-l-aspartate (PALA) and methotrexate in advanced colorectal carcinoma